NewAmsterdam Pharma (NASDAQ:NAMS) Shares Bought by GSA Capital Partners LLP

GSA Capital Partners LLP lifted its position in shares of NewAmsterdam Pharma (NASDAQ:NAMS) by 79.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 66,402 shares of the company’s stock after purchasing an additional 29,496 shares during the period. GSA Capital Partners LLP owned about 0.07% of NewAmsterdam Pharma worth $1,102,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of NAMS. Millennium Management LLC lifted its holdings in shares of NewAmsterdam Pharma by 23.0% in the 2nd quarter. Millennium Management LLC now owns 1,165,429 shares of the company’s stock valued at $22,388,000 after purchasing an additional 217,902 shares during the last quarter. Deerfield Management Company L.P. Series C boosted its holdings in shares of NewAmsterdam Pharma by 30.3% in the second quarter. Deerfield Management Company L.P. Series C now owns 869,250 shares of the company’s stock valued at $16,698,000 after acquiring an additional 202,250 shares during the period. Artal Group S.A. purchased a new position in shares of NewAmsterdam Pharma during the first quarter worth approximately $18,920,000. Janus Henderson Group PLC acquired a new position in shares of NewAmsterdam Pharma in the 1st quarter valued at $15,018,000. Finally, Affinity Asset Advisors LLC raised its position in NewAmsterdam Pharma by 47.9% in the 2nd quarter. Affinity Asset Advisors LLC now owns 423,155 shares of the company’s stock valued at $8,129,000 after purchasing an additional 136,955 shares during the last quarter. 89.89% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on NAMS shares. Royal Bank of Canada reissued an “outperform” rating and set a $31.00 price objective on shares of NewAmsterdam Pharma in a research report on Thursday, September 5th. Piper Sandler restated an “overweight” rating and issued a $37.00 price target on shares of NewAmsterdam Pharma in a research report on Monday, September 23rd. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $36.00 price objective on shares of NewAmsterdam Pharma in a research report on Thursday, November 7th. Seven analysts have rated the stock with a buy rating, According to MarketBeat, NewAmsterdam Pharma presently has a consensus rating of “Buy” and an average target price of $33.80.

NewAmsterdam Pharma Trading Up 1.5 %

Shares of NewAmsterdam Pharma stock opened at $24.97 on Friday. NewAmsterdam Pharma has a 52-week low of $8.90 and a 52-week high of $26.35. The company’s 50-day simple moving average is $18.18 and its 200-day simple moving average is $18.56.

Insider Activity at NewAmsterdam Pharma

In related news, CAO Louise Frederika Kooij sold 45,000 shares of the business’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $15.72, for a total transaction of $707,400.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 19.50% of the company’s stock.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.